ethyl N^α-(L-leucyl)-1-methyl-D-tryptophanate hydrochloride | 2071683-99-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl N^α-(L-leucyl)-1-methyl-D-tryptophanate hydrochloride
• 英文别名: Ethyl leucyl-1-methyl-D-tryptophanate hydrochloride；ethyl (2R)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-(1-methylindol-3-yl)propanoate;hydrochloride
• CAS: 2071683-99-1
• 化学式: C₂₀H₂₉N₃O₃*ClH
• 分子量: 395.93
• InChiKey: PXFDVONNVFXYEP-MCJVGQIASA-N

物化性质

• 溶解度：
  DMSO：250 mg/mL（631.44 mM；需要超声波）

计算性质

• 辛醇/水分配系数(LogP)：
  2.56
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  86.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-甲基-D-色氨酸 在 盐酸 、 氯化亚砜 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 生成 ethyl N^α-(L-leucyl)-1-methyl-D-tryptophanate hydrochloride
  参考文献：
  名称：

  Discovery of indoximod prodrugs and characterization of clinical candidate NLG802

  摘要：

  A series of different prodrugs of indoximod, including estesrs and peptide amides were synthesized with the aim of improving its oral bioavailability in humans. The pharmacokinetics of prodrugs that were stable in buffers, plasma and simulated gastric and intestinal fluids was first assessed in rats after oral dosing in solution or in capsule formulation. Two prodrugs that produced the highest exposure to indoximod in rats were further tested in Cynomolgus monkeys, a species in which indoximod has oral bioavailability of 6-10% and an equivalent dose-dependent exposure profile as humans. NLG802 was selected as the clinical development candidate after increasing oral bioavailability (>5-fold), C-max (6.1 -3.6 fold) and AUC (2.9-5.2 fold) in monkeys, compared to equivalent molar oral doses of indoximod. NLG802 is extensively absorbed and rapidly metabolized to indoximod in all species tested and shows a safe toxicological profile at the anti-cipated therapeutic doses. NLG802 markedly enhanced the anti-tumor responses of tumor-specific pmel-1 T cells in a melanoma tumor model. In conclusion, NLG802 is a prodrug of indoximod expected to increase clinical drug exposure to indoximod above the current achievable levels, thus increasing the possibility of therapeutic effects in a larger fraction of the target patient population. (C) 2020 The Authors. Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2020.112373

文献信息

• SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN
  申请人：NewLink Genetics, Corp.

  公开号：US20170022157A1

  公开（公告）日：2017-01-26

  Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.

  目前提供的是吲哚氧化酶抑制剂前药和盐类化合物，以及包含吲哚氧化酶抑制剂前药和盐类的药物组合物，相比直接给予吲哚氧化酶抑制剂，这些组合物在需要治疗由吲哚胺-2,3-二氧化酶途径介导的免疫抑制的患者中，如癌症或慢性传染病患者，能够产生增强的血浆浓度和暴露于吲哚氧化酶抑制剂。